[Acquired Aplastic Anemia Developing Myelodysplastic Syndrome/acute Myeloid Leukemia: Clinical Analysis of Nineteen Patients and Literatures Review]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2015 Apr 10

PMID 25854465

Authors

Li Ma

Xingxin Li

Jing Zhang

Yingqi Shao

Neng Nie

Zhendong Huang

Meili Ge

Yizhou Zheng

Dongxia Qu

Jun Shi

Affiliations

Soon will be listed here.

Abstract

Objective: To analyze the clinical features of clonal evolution of acquired aplastic anemia (AA) into myelodysplastic syndrome/acute myeloid leukemia (AML) and review of literatures.

Methods: AA developing MDS/AML patients between December 1994 and December 2011 enrolled into this study to analyze their clinical characteristics.

Results: During the median follow-up of 49(15-97) months, 19 patients evolved to MDS/AML, of whom 10, 8 and 1 were from VSAA, SAA and NSAA subgroups, respectively. The median G-CSF therapy was 270(29-510) days. There were monosomy 7 in 11(57.9%) of 19 patients with AA evolved to MDS/AML. The median AA evolved to MDS/AML was 33(11-88) months. The median MDS/AML transformation in responders (54.2 months) was significantly longer than of non-responders (25.7 months, P<0.01).

Conclusion: AA patients could evolved into MDS/AML concomitant with abnormal karotype and worse prognosis.

References

Young N, Scheinberg P, Calado R . Aplastic anemia. Curr Opin Hematol. 2008; 15(3):162-8. PMC: 3410534. DOI: 10.1097/MOH.0b013e3282fa7470. View

Afable 2nd M, Tiu R, Maciejewski J . Clonal evolution in aplastic anemia. Hematology Am Soc Hematol Educ Program. 2011; 2011:90-5. DOI: 10.1182/asheducation-2011.1.90. View

Calado R, Yewdell W, Wilkerson K, Regal J, Kajigaya S, Stratakis C . Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood. 2009; 114(11):2236-43. PMC: 2745844. DOI: 10.1182/blood-2008-09-178871. View

Scheinberg P, Cooper J, Sloand E, Wu C, Calado R, Young N . Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA. 2010; 304(12):1358-64. PMC: 3721502. DOI: 10.1001/jama.2010.1376. View

Li X, Ge M, Shi J, Feng X, Shao Y, Qian L . [Long-term follow-up of malignant clonal evolution in patients with acquired aplastic anemia]. Zhonghua Xue Ye Xue Za Zhi. 2012; 32(7):463-7. View

Gurion R, Gafter-Gvili A, Paul M, Vidal L, Ben-Bassat I, Yeshurun M . Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica. 2009; 94(5):712-9. PMC: 2675684. DOI: 10.3324/haematol.2008.002170. View

Tichelli A, Schrezenmeier H, Socie G, Marsh J, Bacigalupo A, Duhrsen U . A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow.... Blood. 2011; 117(17):4434-41. DOI: 10.1182/blood-2010-08-304071. View

NAJEAN Y, Haguenauer O . Long-term (5 to 20 years) Evolution of nongrafted aplastic anemias. The Cooperative Group for the Study of Aplastic and Refractory Anemias. Blood. 1990; 76(11):2222-8. View

Kojima S, Ohara A, Tsuchida M, Kudoh T, Hanada R, Okimoto Y . Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood. 2002; 100(3):786-90. DOI: 10.1182/blood.v100.3.786. View

10.

Locasciulli A, Oneto R, Bacigalupo A, Socie G, Korthof E, Bekassy A . Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007; 92(1):11-8. DOI: 10.3324/haematol.10075. View

11.

Saracco P, Quarello P, Iori A, Zecca M, Longoni D, Svahn J . Cyclosporin A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with long-term observation follow-up. Br J Haematol. 2008; 140(2):197-205. DOI: 10.1111/j.1365-2141.2007.06903.x. View

12.

Socie G, Mary J, Schrezenmeier H, Marsh J, Bacigalupo A, Locasciulli A . Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2006; 109(7):2794-6. DOI: 10.1182/blood-2006-07-034272. View

13.

Sloand E, Yong A, Ramkissoon S, Solomou E, Bruno T, Kim S . Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor. Proc Natl Acad Sci U S A. 2006; 103(39):14483-8. PMC: 1599987. DOI: 10.1073/pnas.0605245103. View

14.

Scheinberg P . Prognostic value of telomere attrition in patients with aplastic anemia. Int J Hematol. 2013; 97(5):553-7. DOI: 10.1007/s12185-013-1332-x. View

15.

Li Y, Li X, Ge M, Shi J, Qian L, Zheng Y . Long-term follow-up of clonal evolutions in 802 aplastic anemia patients: a single-center experience. Ann Hematol. 2011; 90(5):529-37. DOI: 10.1007/s00277-010-1140-9. View

16.

Viollier R, Passweg J, Gregor M, Favre G, Kuhne T, Nissen C . Quality-adjusted survival analysis shows differences in outcome after immunosuppression or bone marrow transplantation in aplastic anemia. Ann Hematol. 2004; 84(1):47-55. DOI: 10.1007/s00277-004-0930-3. View

17.

Young N, Bacigalupo A, Marsh J . Aplastic anemia: pathophysiology and treatment. Biol Blood Marrow Transplant. 2009; 16(1 Suppl):S119-25. PMC: 3521519. DOI: 10.1016/j.bbmt.2009.09.013. View